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EU Paediatric Regulation was adopted by the European
Parliament and the Council in December 2006. First
meeting of the Paediatric Committee took place in July
2007.
1. Paediatric investigation Plans (PIPs)
In 2007-2013 The European Medicines Agency (EMA)
and its Paediatric Committee have agreed more than 600
Paediatric Investigation Plans (PIPs) with pharmaceutical
companies, to provide data on the efficacy and safety of
medicines for diseases of children.
· For treatment of JIA PIP was agreed for the following
substances: abatacept, adalimumab, anakinra, anti-BAFF
antibody, anti-IL-6 antibody, anti-IL17 antibody, anti-IL-
17A antibody, apremilast, baricitinib, canakinumab, certo-
lizumab, denosumab, etanercept, givinostat, golimumab,
olokizumab, sarilumab, tocilizumab, tofacitinib and
ustekinumab.
· For treatment of SLE in children PIP was agreed for
anti-BAFF, belimumab and epratuzumab.
· For treatment of CAPS PIP was agreed for anakinra,
anti-IL-1beta antibody and canakinumab.
2. Clinical trials
More paediatric clinical trials were done (data from
EudraCT, accessible at the European Clinical Trials
Register):
3. New authorised indications for children
· 12/11/2009: canakinumab for treatment of CAPS.
· 25/08/2008: adalimumab - treatment of active polyar-
ticular juvenile idiopathic arthritis in adolescents from
13 to 17 years of age.
· 20/01/2010 abatacept - treatment of moderate to
severe active polyarticular juvenile idiopathic arthritis in
paediatric patients 6 years of age and older.
· 18/03/2011 adalimumab - treatment of active polyar-
ticular juvenile idiopathic arthritis in the paediatric
population aged from 4 to 12 years.
· 01/08/2011: tocilizumab - treatment of active systemic
juvenile idiopathic arthritis (sJIA) in patients 2 years of age
and older.
· 24/08/2011: etanercept - polyarticular juvenile idio-
pathic arthritis (JIA) from the age of 2 years.
· 24/08/2012: etanercept - treatment of RF+ and RF-
polyarthritis, extended oligoarthritis from 2 years of age,
psoriatic arthritis and ERA from 12 years of age.
· 17/01/2013 - adalimumab - treatment of active poly-
articular juvenile idiopathic arthritis in the paediatric
population aged from 2 to 4 years old.
· 25/04/2013 - tocilizumab - treatment of polyarthritis
(RF+, RF- and extended oligoarthritis) from 2 years old
(EC decision pending at the time of abstract submission).
4. A network of paediatric research networks
Enpr-EMA works by fostering collaboration from
within and outside the European Union (EU), including
between members, patients associations, academia and
the pharmaceutical industry.) PRINTO and JSWG of
PRES are members of Enpr-EMA.
5. Expert meetings at EMA:
Paediatric rheumatology (2009, 2010), Gastroenterology
and rheumatology (2010).
6. Development of scientific guidelines (JIA, SLE,
GIOP).
7. Pharmacovigilance
ENCEPP - (PharmaChild protocol agreed).
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